Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial-Reference-Cited by-同舟云学术

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

Published:2023-03 Issue:3 Volume:24 Page:273-285
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tolaney Sara M,Tarantino Paolo,Graham Noah,Tayob Nabihah,Parè Laia,Villacampa Guillermo,Dang Chau T,Yardley Denise A,Moy Beverly,Marcom P Kelly,Albain Kathy S,Rugo Hope S,Ellis Matthew J,Shapira Iuliana,Wolff Antonio C,Carey Lisa A,Barroso-Sousa Romualdo,Villagrasa Patricia,DeMeo Michelle,DiLullo Molly,Zanudo Jorge Gomez Tejeda,Weiss Jakob,Wagle Nikhil,Partridge Ann H,Waks Adrienne G,Hudis Clifford A,Krop Ian E,Burstein Harold J,Prat Aleix,Winer Eric P

Funder

Dana-Farber Cancer Institute

Genentech

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials;Bradley;Lancet Oncol,2021

2. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study;Vaz-Luis;J Clin Oncol,2014

3. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller;Gonzalez-Angulo;J Clin Oncol,2009

4. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system;Fehrenbacher;J Clin Oncol,2014

5. A US registry-based assessment of use and impact of chemotherapy in stage I HER2-positive breast cancer;Parsons;J Natl Compr Canc Netw,2018

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update;Journal of Clinical Oncology;2024-09-11

3. Clinical Outcomes in Patients with Early Stage Node-Negative HER2-Positive Breast Cancer Receiving Upfront Surgery or Neoadjuvant Systemic Therapy;Annals of Surgical Oncology;2024-08-27

4. Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies;JCO Oncology Practice;2024-08

5. GSFM: A genome-scale functional module transformation to represent drug efficacy for in silico drug discovery;Acta Pharmaceutica Sinica B;2024-08